It was gradually discovered that the antitumor effect of IMiDs on multiple myeloma and other hematologic diseases is mediated by CRBN either through a ubiquitin-dependent or a ubiquitin-independent pathway. This evidence concerns the gene CRBN and plasma cell myeloma.